InvestorsObserver
×
News Home

Do Traders Think Exelixis Inc (EXEL) Can Keep Climbing Monday?

Monday, March 20, 2023 12:29 PM | InvestorsObserver Analysts

Mentioned in this article

Do Traders Think Exelixis Inc (EXEL) Can Keep Climbing Monday?

Exelixis Inc (EXEL) stock has risen 8.21% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Exelixis Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on EXEL!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With EXEL Stock Today?

Exelixis Inc (EXEL) stock is trading at $18.19 as of 12:14 PM on Monday, Mar 20, a gain of $0.64, or 3.65% from the previous closing price of $17.55. The stock has traded between $18.03 and $18.70 so far today. Volume today is less active than usual. So far 1,624,549 shares have traded compared to average volume of 3,350,578 shares. To see InvestorsObserver's Sentiment Score for Exelixis Inc click here.

More About Exelixis Inc

Exelixis Inc is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Its lead molecule, cabozantinib, is indicated for treating patients with metastatic medullary thyroid cancer under the name Cometriq and for treating kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Click Here to get the full Stock Report for Exelixis Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App